Aradigm to Present at BIO CEO & Investor Conference 2008 on February 13
Posted on: Monday, 4 February 2008, 09:01 CST
Aradigm Corporation (OTCBB:ARDM) today announced that its President and Chief Executive Officer Igor Gonda, Ph.D. will present at the BIO CEO & Investor Conference 2008 on Wednesday, February 13 at 12:30 p.m. Eastern Time (9:30 a.m. Pacific time). The conference is being held at the Waldorf-Astoria Hotel in New York City.
Interested parties can access a live audio webcast and slide presentation at www.aradigm.com. An archived presentation will be available on the Web site for 14 days.
About Aradigm
Aradigm is an emerging specialty pharmaceutical company focused on the development and commercialization of a portfolio of drugs delivered by inhalation for the treatment and prevention of severe respiratory diseases by pulmonologists. Current activities include partnered and self-initiated development programs addressing the treatment of cystic fibrosis, bronchiectasis, pulmonary hypertension, inhalation anthrax infections and smoking cessation. More information about Aradigm can be found at www.aradigm.com.
Aradigm is a registered trademark and the Aradigm Logo is a trademark of Aradigm Corporation.
SOURCE: Aradigm
Source: Business Wire
Related Articles
- Aradigm and Canadian Department of National Defence Extend AERx Liposomal Ciprofloxacin Development Program
- Aradigm and APT Move Asthma Treatment into Phase II
- Aradigm and APT Pharmaceuticals Initiate Phase 2 Clinical Program of Novel Treatment for Asthma
- Aradigm Seeks Orphan Drug Status for Cystic Fibrosis Candidate
- Aradigm and United Therapeutics Sign Development and Commercialization Agreement Targeting Pulmonary Hypertension
- Aradigm and APT Pharmaceuticals Announce Progression of AERx HCQ Program Into Phase 2 Clinical Trials
- Aradigm Advances Development of Intraject Sumatriptan With New Clinical Trial Data
- Aradigm Expands Financial and Strategic Strength on Closing of Restructured Licensing Agreement With Novo Nordisk
- Aradigm Announces $12.5M Private Placement Financing
- Aradigm Announces Results From Clinical Study of Intraject Needle-Free System With Sumatriptan
 |
 |
User Comments (0)
RSS Feeds